Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2009-07-30FDA Approved: LEVETIRACETAM — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for levetiracetam from Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2009-07-28Clinical Trial Update: A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR [Phase 3]
A Phase 3 clinical trial update assessing the efficacy and safety of Keppra Extended Release Formulation (XR) in epilepsy has completed with…
-
FDA approval · 2009-07-09FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Dilantin (extended phenytoin sodium), a formulation of phenytoin used to treat seizures. The sub…
-
CLINICAL_TRIALS trial_result · 2009-07-09Clinical Trial Update: Affective Processing in Depression and Epilepsy
The trial update indicates termination of NCT00855725, a study of affective processing in individuals with epilepsy and major depressive dis…
-
CLINICAL_TRIALS trial_result · 2009-07-08Clinical Trial Update: Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER). [Phase 4]
Phase 4 trial evaluating pregabalin as add-on therapy for partial seizures in epilepsy; completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2009-06-30FDA Approved: LEVETIRACETAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Levetiracetam from Aurobindo Pharma Limited, granting approval for a generic version under the A…
-
FDA approval · 2009-06-29FDA Approved: LEVETIRACETAM — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for LEVETIRACETAM (generic) from BluePoint Laboratories.
-
FDA approval · 2009-06-26FDA Approved: OXCARBAZEPINE — Original Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries' original ANDA for oxcarbazepine, yielding a generic version of this anticonvulsant.
-
FDA approval · 2009-05-29FDA Approved: LAMICTAL XR — Original Application (GlaxoSmithKline LLC)
FDA approved Lamictal XR (lamotrigine) in an original application by GlaxoSmithKline LLC, establishing the extended-release formulation for …
-
CLINICAL_TRIALS trial_result · 2009-05-12Clinical Trial Update: Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies [Phase 4]
Phase 4 clinical trial completed evaluating lamotrigine for cognitive function in adults with untreated epilepsy.
-
FDA approval · 2009-05-08FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for LAMICTAL (lamotrigine) submitted by GlaxoSmithKline LLC.
-
FDA approval · 2009-05-08FDA Approved: MYSOLINE — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for MYSOLINE (primidone) from Bausch Health US, LLC.
-
FDA approval · 2009-05-08FDA Approved: LAMICTAL ODT — Original Application (GlaxoSmithKline LLC)
The FDA approved a new orally disintegrating tablet formulation of lamotrigine (Lamictal ODT). It was approved under GlaxoSmithKline's origi…
-
FDA approval · 2009-05-06FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) by Parke-Davis Div of Pfizer Inc, under the ANDA process.
-
FDA approval · 2009-05-06FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Dilantin (Extended Phenytoin Sodium) submitted by Viatris Specialty LLC.
-
FDA approval · 2009-04-23FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TEGRETOL (carbamazepine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2009-04-23FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) from Parke-Davis (Pfizer). It updates the labeling for the product.
-
FDA label_change · 2009-04-23FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation. The decision involv…
-
FDA approval · 2009-04-23FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN-125 (phenytoin) from Viatris Specialty LLC, adding a new dosage strength to the product…
-
FDA approval · 2009-04-23FDA Approved: CELONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Celontin (methsuximide) from Parke-Davis Div of Pfizer Inc, expanding its labeling for epile…
-
FDA approval · 2009-04-23FDA Approved: KLONOPIN — Supplemental Application (H2-Pharma, LLC)
FDA approved a supplemental NDA for KLONOPIN (clonazepam) submitted by H2-Pharma, LLC.
-
FDA approval · 2009-04-23FDA Approved: FELBAMATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for felbamate (Felbatol) filed by Mylan Pharmaceuticals Inc.
-
FDA approval · 2009-04-23FDA Approved: TEGRETOL XR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol XR (carbamazepine) submitted by Novartis Pharmaceuticals, indicating an approved modifi…
-
FDA approval · 2009-04-23FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA XR (levetiracetam) by UCB, Inc., related to the extended-release formulation.
-
FDA approval · 2009-04-23FDA Approved: TIAGABINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for tiagabine hydrochloride under NDA No. NDA020646, managed by Teva Pharmaceuticals USA, Inc.